GlassScriptPhysician profile
Troyanna L Egan
NPI 1558143370
$2,339.37
in general payments reported to CMS, 2019-2025
14 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,227 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $674.86 | 2024-2025 | Gemtesa, Orgovyx |
| Endo USA, INC. | $317.25 | 2024-2025 | Xiaflex, Aveed |
| Astrazeneca Pharmaceuticals LP | $237.50 | 2024-2025 | Lynparza |
| Janssen Biotech, INC. | $214.61 | 2024-2025 | Erleada, Akeega, Balversa |
| Ferring Pharmaceuticals INC. | $201.20 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $152.29 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.85 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $111.32 | 2024-2025 | Keytruda, Welireg |
| Tolmar, INC. | $110.46 | 2024-2025 | Eligard, Jatenzo |
| Endo Pharmaceuticals INC. | $64.33 | 2024 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $39.20 | 2025 | |
| Dendreon Pharmaceuticals LLC | $27.80 | 2025 | Provenge |
| Procept Biorobotics Corporation | $27.53 | 2024 | Aquabeam System |
| Novartis Pharmaceuticals Corporation | $15.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troyanna Egan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.